Galera Therapeutics Inc., of Malvern, Pa., said it completed enrollment in its phase IIb study testing GC-4419, a dismutase mimetic, in reducing the incidence and duration of oral mucositis (OM) in head and neck cancer patients receiving chemoradiation therapy.